Quick viewing(Text Mode)

TVCN Blank Document

TVCN Blank Document

Thames Valley

Appendix 1: Emetic risk of haematology regimens Lymphoma High emetogenic risk Moderate emetogenic risk Low emetogenic risk Minimal emetogenic risk ABVD / R-Bendamustine / O-bendamustine Alemtuzumab BEACOPDac-14 / BEACOP-DAc- Escalated DRC Brentuximab vedotin ChIVPP / + Rituximab (FCR) Ibrutinib ORAL Weekly CHOEP High-dose (>1000mg/m2) Nivolumab DA-EPOCH-R High-dose Methotrexate >1000mg/m2 / - HLH E-SHAP/R-E-SHAP R-BAC and Chlorambucil Rituximab High dose METHOTREXATE and high dose CYTARABINE MeAD Ofatumumab and Chlorambucil Obinutuzumab MATRix R-CP Ofatumumab MaxiCHOP R-CVP/O-CVP R-VP Mini-BEAM R-GemOx R-CODOX-M / R-IVAC R-GCVP R-CHOP/CHOP / Mini-CHOP R-GDP R-Hyper-CVAD / R-MA SMILE

Myeloid High emetogenic risk Moderate emetogenic risk Low emetogenic risk Minimal emetogenic risk FLA-IDA/ FLAG-IDA ADE ALL maintenance Blinatumumab HD Ara-C + ALL Phase 1 Induction ATRA + MACE ALL Phase 2 Induction Dasatinib Chlorambucil ALL intensification/CNS prophylaxis (HDMXT) Etoposide Oral Cladribine Gemtuzumab Ozogomicin Bosutinib DA EZ FLA/FLAG Nilotinib High-dose ARA-C (>1g/m2) Ponatinib LD-ARA-C and MidAC Nelarabine/Cyclophosphamide/Etoposide (Nel-Cyc-Etop)

Filename: TVCN Anti-emetic Policy Page 1 of 3 Issue Date: September 2019 Version: 8.2a Agreed by Chair Network Group Review Date: September 2021

Thames Valley

Myeloma High emetogenic risk Moderate emetogenic risk Low emetogenic risk Minimal emetogenic risk CarLenDex/CarDex DTPACE Cyclophosphamide +/- Prednisolone (/Lenalidomide/Dexamethasone) /Dexamethasone Dara/Len/Dex VTDPACE BTD (Bendamustine//Dex) (/Lenalidomide/Dexamethadone) Carfilzomib/Dexamethasone Dara/Bor/Dex BVD (Bendamustine/Bortezomib/Dex) (Daratumumab/Bortezomib/Dexamethasone) Daratumumab Monotherapy (PO) +/- Cyclophosphamide +/- Prednisolone Lenalidomide +/- Dexamethasone Prednisolone Z-DEX ( PO + Dex) MelBorPred (Melphalan/Bortezomib/prednisolone) Sultuximab CTD/CTDa (Cyclophsphamide/Thalidomide/Dexamethasone)- on weekly cyclophosphamide days MPT (Melphalan PO /Prednisolone/Thalidomide) CyBorDex (Cyclophsphamide/Bortezomib/Dexamethasone)- on weekly cyclophosphamide days + Dexamethasone CyCarDex (Cyclophosphamide/Carfilzomib/Dexamethasone)- on weekly cyclophosphamide days Thalidomide + Dexamethasone Cy/Len.Dex (Cyclophosphamide/Lenalidomide/Dexamethasone)- on weekly cyclophosphamide days VRD (Bortezomib/Lenalidomide/Dexamethasone) IRD (/Lenalidomide/Dexamethasone)- on weekly Ixazomib days VTD (Bortezomib/Thalidomide/Dexamethasone) PanBorDex (/Bortezomib/Dexamethasone)- on panobinostat days RCD (Lenalidomide/Cyclophsphamide/Dexamethasone)- on weekly cyclophosphamide days

Filename: TVCN Anti-emetic Policy Page 2 of 3 Issue Date: September 2019 Version: 8.2a Agreed by Chair Network Chemotherapy Group Review Date: September 2021

Thames Valley

Bone Marrow Transplant (Allograft & Autograft) High emetogenic risk Moderate emetogenic risk Low emetogenic risk Minimal emetogenic risk Fludarabine/Cyclophosphamide/ATG +/- TBI BCNU (high dose) (high risk if having TBI) Fludarabine/Cyclophosphamide/Alemtuzumab BEAM +/- TBI (high risk if having TBI) BEAM Campath Fludarabine/Melphalan Busulfan/Cyclophosphamide Fludarabine/ Melphalan /Alemtuzumab Busulfan/Fludarabine/ATG /Melphalan for Autograft Cyclophosphamide Priming Cyclophosphamide/ATG (allograft) Cyclophosphamide /ATG Conditioning Autograft (CROHN’S AUTOLOGOUS TRANSPLANTATION) Cyclophosphamide/Fludarabine/ TBI Cyclophosphamide/TBI Cyclophosphamide/TBI/Alemtuzumab FLAMSA-BU High Dose Melphalan for Autograft LEAM Thiotepa/Busulfan/Fludarabine/ATG Total Lymphoid Irradiation (TLI)/Rabbit Anti- Thymocyte Globulin (rbATG) for Non- myeloablative Allograft TopCat ( / / Thiotepa)

Filename: TVCN Anti-emetic Policy Page 3 of 3 Issue Date: September 2019 Version: 8.2a Agreed by Chair Network Chemotherapy Group Review Date: September 2021

Top View